Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CJEU Confirms Settlements Can Break EU Law

In Ruling Related To ‘Pay For Delay’ Deals Over Paroxetine

Executive Summary

The UK’s Competition and Markets Authority has welcomed a formal ruling by the CJEU that settling patent disputes can break EU law by restricting competition and abusing a dominant position, in a case revolving around so-called ‘pay for delay’ settlements over GSK’s Seroxat paroxetine antidepressant.

You may also be interested in...



UK Reduces Fines On Paroxetine Pay-For-Delay

Fines imposed on firms including Actavis, Alpharma, Generics UK and Xellia as well as GlaxoSmithKline have been reduced following Competition Appeal Tribunal ruling that nevertheless upheld a finding of competition law infringement linked to historical pay-for-delay deals.

EU Investigates Teva For Undermining Copaxone Generics

The European Commission is investigating whether Teva “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.

Teva Under Investigation For Creating ‘False Perceptions’ Of Generics

The European Commission is investigating whether Teva has “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel